Davidigenin

Davidigenin

SCHEMBL750182

O=C(CCc1ccc(O)cc1)c1ccc(O)cc1O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.70
ESR1 P03372 2/20 0.69
SHBG P04278 1/20 0.69
ESR2 Q92731 1/20 0.69
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
LMNA P02545 3/20 0.67
SLC5A1 P13866 3/20 0.67
SLC5A2 P31639 3/20 0.67
GAA P10253 2/20 0.67
MAPT P10636 2/20 0.67
ALDH1A1 P00352 2/20 0.67
CYP3A4 P08684 2/20 0.67
HPGD P15428 2/20 0.67
ATM Q13315 2/20 0.67
KDM4E B2RXH2 1/20 0.67
SLC16A3 O15427 1/20 0.67
TTR P02766 1/20 0.67
TP53 P04637 1/20 0.67
CYP1A2 P05177 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Davidigenin SCHEMBL30291870 1.00 CYP19A1 (0.70) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL7301852 0.90 GAA (0.66) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL30065457 0.90 GAA (0.66) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL31511905 0.88 CYP19A1 (0.67) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL9578017 0.88 CYP19A1 (0.67) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL31511903 0.88 MEN1 (0.76) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL4656453 0.88 MEN1 (0.76) CYP19A1ESR1SHBGESR2MEN1
SCHEMBL2875989 0.85 KMT2A (0.69) CYP19A1ESR1ESR2MEN1KMT2A
SCHEMBL30254972 0.85 KMT2A (0.69) CYP19A1ESR1ESR2MEN1KMT2A
SCHEMBL6427459 0.85 HSP90AB1 (0.70) ESR1SHBGESR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293614-A1 COMPOSITIONS AND METHODS OF TREATING UPS-ASSOCIATED DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-09-21 US claimed
US-20230045522-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-02-09 US claimed
US-11234918-B2 Methods for botanical and/or algae extraction BASF CORPORATION (US) 2022-02-01 US claimed
WO-2022015740-A1 COMPOSITIONS AND METHODS OF TREATING UPS-ASSOCIATED DISEASES BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2022-01-20 WO claimed
WO-2021113473-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2021-06-10 WO claimed
US-20200397026-A1 ANTIMICROBIALLY ACTIVE MIXTURES SYMRISE AG (DE) 2020-12-24 US claimed
EP-3709820-A1 ANTIMICROBIALLY ACTIVE MIXTURES Symrise AG (DE) 2020-09-23 EP claimed
EP-2858641-B1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORP (US) 2017-09-06 EP claimed
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) 2015-05-21 US claimed
EP-2858641-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF Corporation (US) 2015-04-15 EP claimed
US-20080227867-A1 USE OF 4-HYDROXYCHALCONE DERIVATIVES FOR MASKING AN UPLEASANT TASTE SYMRISE GMBH & CO. KG (DE) 2008-09-18 US claimed
WO-2007109217-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO claimed
WO-2007107596-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO. KG (DE) 2007-09-27 WO claimed
US-20070224301-A1 Compounds from an extract of Artemisia and methods for treating disorders RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-09-27 US claimed
CN-101022818-A Physiologically active composition CARGILL INC (US) 2007-08-22 CN claimed
EP-1818060-A1 Cosmetic composition comprising Fadogia ancylantha extracts ARTSANA S.p.A. (IT) 2007-08-15 EP claimed
EP-1784201-A2 PHYSIOLOGICALLY ACTIVE COMPOSITION Cargill, Incorporated (US) 2007-05-16 EP claimed
WO-2006010560-A2 PHYSIOLOGICALLY ACTIVE COMPOSITION CARGILL, INCORPORATED (US) 2006-02-02 WO claimed
US-5234951-A Anti-ulcer agent comprising chalcone derivative TSUMURA JUNTENDO, INC. (JP) 1993-08-10 US claimed
EP-0292576-A1 ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES TSUMURA & CO. (JP) 1988-11-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11234918-B2 Methods for botanical and/or algae extraction ALG1, ALG8, CUTA CYP19A1 1745/4885ESR1 4633/4885SHBG 362/4885
US-20070224301-A1 Compounds from an extract of Artemisia and methods for treating disorders PDK2, PCK2, DUSP2 CYP19A1 909/4885ESR1 2944/4885SHBG 2357/4885
US-20080227867-A1 USE OF 4-HYDROXYCHALCONE DERIVATIVES FOR MASKING AN UPLEASANT TASTE TAS2R45, TAS2R43, TAS2R30 CYP19A1 4132/4885ESR1 2960/4885SHBG 391/4885
US-20230045522-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS GCKR, G6PC1, GPR119 CYP19A1 1822/4885ESR1 1818/4885SHBG 245/4885
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION ALG1, ALG8, CUTA CYP19A1 1745/4885ESR1 4633/4885SHBG 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.